<div id="readability-page-1" class="page"><div id="parent_top_div">In a market shaped by global tensions and shifting sector dynamics, brokerage firm Prabhudas Lilladher (PL Capital) is advising investors to stay grounded—but not passive. At its recent PL Alpha: India View webinar, the firm brought together senior research and advisory voices to decode what lies ahead for Indian equities. The message was clear: brace for volatility, but don’t lose sight of India’s structural strength. According to Amnish Aggarwal, Co-Head – Institutional Equities, the past few weeks have been marked by sharp swings, largely driven by rising geopolitical tensions involving the US, Israel, and Iran. Yet, India has held up relatively well. Policy interventions—such as cuts in oil taxes—have helped cushion immediate shocks. But Aggarwal cautioned that the real impact may still be building beneath the surface. Higher crude prices could trigger second-order effects, pushing inflation higher in the coming months and potentially forcing a reset in growth and earnings expectations. For investors, that means one thing: don’t confuse short-term stability with long-term immunity. Advisory view: Focus on structural themes and stock opportunities: Vikram Kasat, Vikram Kasat (Head –Advisory) From an advisory standpoint, Vikram Kasat, Head – Advisory, highlighted a shift in how capital is being deployed. Instead of broad-based bets, investors—especially HNIs and institutions—are gravitating toward high-conviction, theme-driven opportunities. Key sectors in focus include: <ul> <li> Logistics, powered by e-commerce growth</li> <li> Ethanol, backed by government blending policies</li> <li> Healthcare, offering defensive stability</li> </ul> At the same time, newer-age themes are gaining traction: <ul> <li> Artificial intelligence</li> <li> Robotics</li> <li> Specialized manufacturing</li> </ul> This signals a deeper transition in markets—from cyclical chasing to structural investing. Markets in a Holding Pattern On the technical side, the outlook is more measured. Vaishali Parekh (Technical Research) and Shilpa Rout (Derivatives Research) pointed to a range-bound market, with indices like Nifty moving within a wide band as investors wait for clearer triggers. <ul> <li> Defined support and resistance levels are in play</li> <li> Momentum is selective, not broad-based</li> </ul> Sectorally: Metals, banks, and autos are showing strength Textiles and chemicals may be nearing a turnaround phase In other words, this isn’t a market for blanket bets—it’s a market for precision. Sectoral strategy: Defensive resilience and cyclical recovery plays Throughout the deliberations, the following two-pronged investment strategy emerged as key: Defensive posture in industries like pharmaceuticals and utilities during uncertain times Cyclical play in capital goods, metals, cement, and engineering, especially in case of de-escalation in geopolitics Capital goods, defense, and infra-related sectors remain strong structural growth bets. Cautious optimism amid uncertainty It is important to be careful of international events that may affect issues like inflation, fiscal deficits, and profit margins through their spill-over effects. However, despite some hitches encountered during the discussion, the experts managed to communicate critical aspects of their strategies effectively. PL Capital’s core message to investors is nuanced but actionable: Stay cautious, because global risks—from inflation to fiscal pressures—are real Stay opportunistic, because India’s macro fundamentals remain strong The current market isn’t about aggressive risk-taking or complete withdrawal. It’s about: <ul> <li> Choosing quality over quantity</li> <li> Maintaining diversification</li> <li> Being selective with sectors and themes</li> </ul></div></div>

生物科技 ETF - VanEck Vectors

南方恆生生物科技ETF(QDII)

華夏上證科創板生物醫藥ETF

在最近的一場網絡研討會上，券商 Prabhudas Lilladher（PL Capital）建議投資者在全球緊張局勢影響市場的情況下保持謹慎但又要抓住機會。專家強調關注結構性主題和高信念投資的重要性，特別是在物流、乙醇和醫療保健等行業。他們指出，儘管印度表現出韌性，但原油價格上漲可能會影響通脹和增長預期。市場目前處於區間震盪狀態，需要在投資策略上保持精準，雙重關注防禦性行業和週期性復甦機會。總體而言，信息強調質量重於數量，以及選擇性參與特定行業

Where should you invest in 2026? Experts at PL Capital decode the best bets

Business Standard

印度 MSCI ETF - iShares

Avantis Emerging Markets Equity ETF

醫療業 ETF - Vanguard

中國 MSCI ETF - iShares

GX印度精選十強

國泰中證生物醫藥ETF

SPDR標普新興市場高股利ETF

安碩印度

華夏印度

華夏醫藥ETF

iShares MSCI EM Ex-China

Vanguard富時新興市場指數ETF

2 倍做空納斯達克生物技術 ETF - ProShares

FIL Ltd.

鵬華上證科創板生物醫藥ETF

華夏中證生物科技主題ETF

華安恆生生物科技ETF

天弘國證生物醫藥ETF

標普新興亞太 ETF - SPDR

美國制藥 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

華夏恆生生物科技ETF(QDII)

iShares MSCI新興市場ETF

醫療業 ETF - SPDR

富國恆生港股通創新藥及醫療保健ETF

WisdomTree新興市場高收益股票基金

易方達滬深300醫藥ETF

Dimensional Emerging Markets Value ETF

iShares安碩核心MSCI新興市場ETF

動態生物技術與基因組 ETF - Invesco

基因改革 ETF - ARK

華寶恆生港股通創新藥精選ETF

標普生物技術 3 倍做多 - Direxion

招商中證生物科技主題ETF

BlackRock, Inc.

Schwab新興市場股票ETF

易方達中證生物科技主題ETF

博時恆生港股通創新藥精選ETF

醫藥突破 ETF - ALPS

創新藥

生物科技ETF基金

華夏印度-R

Avantis Emerging Markets Value ETF

博時恆生醫療保健(QDII-ETF)

紐交所高增長板生物技術指數 ETF - First Trust

標普全球醫療股指數 ETF - iShares

香港醫藥

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 ETF - SPDR

易方達恆生港股通創新藥ETF

iShares MSCI Emerging Mkts Val Fac ETF

標普生物技術 3 倍做空 - Direxion

新興市場亞洲 MSCI ETF - iShares

Invesco Nasdaq Biotechnology ETF

廣發中證香港創新藥(QDII-ETF)

iShares MSCI新興市場綜合因素ETF

SPDR新興市場投資組合ETF

華夏印度-U

2026 年應該在哪裏進行投資？PL Capital 的專家為您解讀最佳投資選擇